Oncology Clinical Trials in Sioux Falls, SD

As of June 2026, 99 paid clinical trials are recruiting for Oncology in Sioux Falls, South Dakota. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

99 clinical trials for Oncology

·Clear filters·↓ Download CSV

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

for Melanoma

Drug: Cemiplimab

23 locations incl. Phoenix

Sponsor: Vyriad, Inc.

Sex: All·Age: 18+

Code: NCT04291105·Phase 2·Recruiting

Apply to this trial

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

for Prostate Adenocarcinoma

Drug: Apalutamide

345 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT04134260·Phase 3·Recruiting

Apply to this trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostate Cancer

25 locations incl. Duarte

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT04221542·Phase 1·Recruiting

Apply to this trial

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04165070·Phase 1, Phase 2·Recruiting

Apply to this trial

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT04165798·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

203 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting

Apply to this trial

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

for Colorectal Cancer

146 locations incl. Millville

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: 60+

Code: NCT03998202·Recruiting

Apply to this trial

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

for Breast Cancer

451 locations incl. Fairbanks

Sponsor: Canadian Cancer Trials Group

Sex: Female·Age: 35+

Code: NCT03488693·Phase 3·Recruiting

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

65 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

100 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

152 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

676 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting

Apply to this trial

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

for Breast Cancer Screening

11 locations incl. Birmingham

Sponsor: University of California, San Francisco

Sex: Female·Age: 30 - 74·Accepts healthy volunteers

Code: NCT02620852·Recruiting

Apply to this trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for Lymphoma, Non-Hodgkin

174 locations incl. Birmingham

Sponsor: American Society of Clinical Oncology

Sex: All·Age: 12+

Code: NCT02693535·Phase 2·Recruiting

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

245 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting

Apply to this trial

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

for Melanoma

7 locations incl. Aurora

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 17

Code: NCT02332668·Phase 1, Phase 2·Recruiting

Apply to this trial

A Long-term Extension Study of PCI-32765 (Ibrutinib)

for Chronic Lymphocytic Leukemia

Drug: Ibrutinib

32 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT01804686·Phase 3·Recruiting

Apply to this trial

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

for Hematologic Malignancies

142 locations incl. Birmingham

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: All ages

Code: NCT01351545·Recruiting

Apply to this trial

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

for Breast Neoplasms

42 locations incl. Birmingham

Sponsor: QuantumLeap Healthcare Collaborative

Sex: All·Age: 18+

Code: NCT01042379·Phase 2·Recruiting

Apply to this trial

Conditions in Oncology (Sioux Falls, SD)

Breast cancer· 17 Non-small cell lung cancer (NSCLC)· 13 Solid tumor· 12 Ovarian cancer· 11 Endometrial cancer· 8 Melanoma· 6 Cancer (any)· 6 Non-Hodgkin lymphoma· 5 Diffuse large B-cell lymphoma (DLBCL)· 5 Colorectal cancer· 4 Gastroesophageal junction cancer· 4 Prostate cancer· 4 Fallopian tube cancer· 4 Acute myeloid leukemia (AML)· 4 Hematologic malignancy· 4 Head and neck cancer· 4 Metastatic breast cancer· 3 Esophageal cancer· 3 Neuroblastoma· 3 Triple-negative breast cancer· 2 HER2-negative breast cancer· 2 Colon cancer· 2 Kidney cancer· 2 Chronic lymphocytic leukemia (CLL)· 2 Acute lymphoblastic leukemia· 2 Leukemia (other)· 2 Myelodysplastic syndromes (MDS)· 2 Hodgkin lymphoma· 2 Mantle cell lymphoma· 2 HER2-positive breast cancer· 1 Lung cancer· 1 Rectal cancer· 1 Pancreatic cancer· 1 Gastric cancer· 1 Biliary tract cancer· 1 Uterine cancer· 1 Gynecologic cancer· 1 Multiple myeloma· 1 Myeloproliferative neoplasm· 1 Follicular lymphoma· 1 Small lymphocytic lymphoma· 1 Burkitt lymphoma· 1 Sarcoma· 1 Osteosarcoma· 1 Ewing sarcoma· 1